Avantor, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Jul 30, 2021 and accepted by EDGAR at Jul 30, 2021, 09:03 ET.
Management's discussion and analysis
As filed, 26,304 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to historical financial information, this discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our results may differ materially from those contained in or implied by any forward-looking statements. You should carefully read “Cautionary factors regarding forward-looking statements” for additional information.
Basis of presentation
This discussion should be read in conjunction with the accompanying condensed consolidated financial statements and notes. Pursuant to SEC rules for reports covering interim periods, we have prepared this discussion and analysis to enable you to assess material changes in our financial condition and results of operations since December 31, 2020, the date of our Annual Report. Therefore, we encourage you to read this discussion and analysis in conjunction with the Annual Report.
Overview
We are a leading global provider of mission critical products and services to customers in the biopharmaceutical, healthcare, education & government and advanced technologies & applied materials industries. We have global operations and an extensive product portfolio. We strive to enable customer success through innovation, cGMP manufacturing and comprehensive service offerings. The depth and breadth of our portfolio provides our customers a comprehensive range of products and services and allows us to create customized and integrated solutions for our customers.
We completed the acquisitions of Ritter GmbH and RIM Bio in the second quarter. These acquisitions did not materially impact the results of our operations for the three and six months ended June 30, 2021.
In the second quarter of 2021, we recorded net sales of $1,858.6 million, net income of $157.8 million and Adjusted EBITDA of $366.6 million. Net sales increased by 25.7%, which included 20.5% organic growth compared to the same period in 2020. See “Reconciliations of non-GAAP measures” for a reconciliation of net income to Adjusted EBITDA and “Results of operations” for a reconciliation of net sales growth to organic net sales growth.
Factors and current trends affecting our business and results of operations
The following updates the factors and current trends disclosed in the Annual Report. These updates could affect our performance and financial condition in future periods.
Our results continue to be impacted by the ongoing global coronavirus outbreak
The results for each of our three regions continue to be impacted by the COVID-19 pandemic for the three and six months ended June 30, 2021, as described further in the “Results of operations” section below.
For a discussion of the impact of the COVID-19 pandemic and associated economic disruptions, and the actual operational and financial impacts that we experienced through December 31, 2020, see “Part II—Item 7—Management's discussion and analysis of financial condition and results of operations” in the Annual Report. For additional discussion of the potential impact of the COVID-19 pandemic and associated economic disruptions to the Company, see “The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, operating results, cash flows and/or financial condition, the nature and extent of which could be material.” included in “Part I—Item 1A—Risk factors” in the Annual Report.
Key indicators of performance and financial condition
To evaluate our performance, we monitor a number of key indicators including certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business.
The key indicators that we monitor are as follows:
- Net sales, gross margin, operating income and net income or loss. These measures are discussed in the section entitled “Results of operations;”
- Organic net sales growth, which is a non-GAAP measure discussed in the section entitled “Results of operations.” Organic net sales growth eliminates from our reported net sales the impacts of earnings from any acquired or disposed businesses and changes in foreign currency exchange rates. The acquisitions of Ritter GmbH and RIM Bio did not materially impact the results of our operations for the three and six months ended June 30, 2021. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measurement is used by our management for the same reason. Reconciliations to the change in reported net sales, the most directly comparable GAAP financial measure, are included in the section entitled “Results of operations;”
- Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP measures discussed in the section entitled “Results of operations.” Adjusted EBITDA is used by investors to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measurements are useful to investors as a way to analyze the underlying trends in our core business consistently across the periods presented. This measurement is used by our management for the same reason. A reconciliation of net income or loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA is included in the section entitled “Reconciliations of non-GAAP measures;”
- Cash flows from operating activities, which we discuss in the section entitled “Liquidity and capital resources—historical cash flows;”
- Free cash flow, which is equal to our cash flow from operating activities, plus acquisition-related costs paid in the period, less capital expenditures. We have amended our definition of free cash flow to exclude acquisition-related costs as they may be significant, individually or in aggregate, and may make it more difficult for investors to understand the free cash flows associated with the normal operations of our business. We believe that this measurement is useful to investors as it provides a view on the Company’s ability to generate cash for use in financing or investment activities. This measurement is used by management for the same reason.
Results of operations
We present results of operations in the same way that we manage our business, evaluate our performance and allocate our resources. We also provide discussion of net sales and Adjusted EBITDA by geographic segment based on customer location: Americas, Europe and AMEA. Corporate costs are managed on a standalone basis and not allocated to segments.
Executive summary
(dollars in millions)
| 2021 | Three months ended June 30, 2020 | Change | |
|---|---|---|---|
| Net sales | $1,858.6 | $1,478.7 | $379.9 |
| Gross margin | 33.7% | 33.2% | 50 bps |
| Operating income | $254.7 | $166.6 | $88.1 |
| Net income | 157.8 | 60.2 | 97.6 |
| Adjusted EBITDA | 366.6 | 273.3 | 93.3 |
| Adjusted EBITDA margin | 19.7% | 18.5% | 125 bps |
Second quarter revenue growth reflects strong growth in the biopharma, healthcare, education & government and advanced technologies & applied materials end markets. Our core business continues to show a strong recovery as the global economy reopens following COVID-19 lockdowns. This growth was augmented by our COVID-19 related sales of PPE and solutions to support diagnostic testing and vaccine production. Double-digit growth of our proprietary materials and consumables product group, commercial excellence, productivity and cost containment contributed to gross margin and Adjusted EBITDA margin expansion.
Net sales
Three months ended
(in millions)
| 2021 | Three months ended June 30, Net sales growth 2020 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth Organic net sales growth | ||
|---|---|---|---|---|---|
| Americas | $1,069.8 | $857.5 | $212.3 | $9.6 | $202.7 |
| Europe | 666.0 | 521.0 | 145.0 | 59.0 | 86.0 |
| AMEA | 122.8 | 100.2 | 22.6 | 6.2 | 16.4 |
| Total | $1,858.6 | $1,478.7 | $379.9 | $74.8 | $305.1 |
Net sales increased $379.9 million or 25.7%, which included $74.8 million or 5.2% of favorable foreign currency impact. Organic growth in net sales was $305.1 million or 20.5% and was primarily due to strong growth in our core business and a modest contribution from COVID-19 related sales. The acquisitions of Ritter GmbH and RIM Bio did not materially impact the results of our operations for the three months ended June 30, 2021.
In the Americas, net sales increased $212.3 million or 24.8%, which included $9.6 million or 1.2% of favorable foreign currency impact. Organic growth in net sales was $202.7 million or 23.6%. Additional information by end market is as follows:
- Biopharma — Sales grew double-digits, with strong growth in biopharma production led by COVID-19 vaccine-related offerings as well as strong growth in the research & development business.
- Healthcare — Sales increased double-digits driven by demand for materials and consumables in our medical/clinical reference lab business, COVID-19 diagnostic testing offerings and increased demand for our proprietary silicone offerings driven by recovery in elective surgical procedures.
- Education and government — Sales increased double-digits primarily from a recovery in education demand from academic labs that had been closed during the prior period due to COVID-19. This contributed to strong growth in university research as lab capacity continues to approach near full levels.
- Advanced technologies & applied materials — Sales increased mid single-digits driven by high single-digit growth of materials and consumables sales to our industrial customers and modest growth in our proprietary offerings into the semiconductor industry.
In Europe, net sales increased $145.0 million or 27.8%, which included $59.0 million or 11.3% of favorable foreign currency impact. Organic growth in net sales was $86.0 million or 16.5%. Additional information by end market is as follows:
- Biopharma — Sales grew in the double-digits driven by single-use solutions to support COVID-19 vaccine production, as well as consumables and PPE.
- Healthcare — Sales grew in the double-digits due to sales of COVID-19 testing content and increased demand for our proprietary silicone offerings driven by recovery in elective surgical procedures.
- Education & government — Sales grew in the double-digits primarily from a recovery in education demand from academic labs that had been closed during the prior period due to COVID-19. This contributed to strong growth in university research as lab capacity continues to approach near full levels.
- Advanced technologies & applied materials — Sales grew in the double-digits as sales of our laboratory materials, consumables and equipment and instrumentation offerings returned to normalized levels.
In AMEA, net sales increased $22.6 million or 22.6%, which included $6.2 million or 6.2% of favorable foreign currency impact. Organic growth in net sales was $16.4 million or 16.4%. Additional information by end market is as follows:
- Biopharma — Sales grew in the double-digits driven by strong growth in proprietary biopharma production materials and single-use offerings.
- Advanced technologies & applied materials — Sales grew mid single-digits primarily driven by double-digit growth of our proprietary offerings into the semiconductor industry.
Six months ended
(in millions)
| 2021 | Six months ended June 30, Net sales growth 2020 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth Organic net sales growth | ||
|---|---|---|---|---|---|
| Americas | $2,104.9 | $1,756.6 | $348.3 | $14.4 | $333.9 |
| Europe | 1,316.4 | 1,065.0 | 251.4 | 110.0 | 141.4 |
| AMEA | 222.9 | 176.1 | 46.8 | 9.9 | 36.9 |
| Total | $3,644.2 | $2,997.7 | $646.5 | $134.3 | $512.2 |
Net sales increased $646.5 million or 21.6%, which included $134.3 million or 4.6% of favorable foreign currency impact. Organic growth in net sales was $512.2 million or 17.0% and was due to both growth in our core business as well as COVID-19 related sales. The acquisitions of Ritter GmbH and RIM Bio did not materially impact the results of our operations for the six months ended June 30, 2021.
In the Americas, net sales increased $348.3 million or 19.8%, which included $14.4 million or 0.8% of favorable foreign currency impact. Organic growth in net sales was $333.9 million or 19.0% for reasons similar to the three month period.
In Europe, net sales increased $251.4 million or 23.6%, which included $110.0 million or 10.3% of favorable foreign currency impact. Organic growth in net sales was $141.4 million or 13.3% for reasons similar to the three month period.
In AMEA, net sales increased $46.8 million or 26.6%, which included $9.9 million or 5.6% of favorable foreign currency impact. Organic growth in net sales was $36.9 million or 21.0% for reasons similar to the three month period.
Gross margin
| 2021 | Three months ended June 30, 2020 | 2021 | Change 2020 | Six months ended June 30, | Change | |
|---|---|---|---|---|---|---|
| Gross margin | 33.7% | 33.2% | 50 bps | 34.0% | 33.1% | 90 bps |
Three and six months ended
Gross margin for the three and six months ended June 30, 2021 increased 50 basis points and 90 basis points, respectively, resulting primarily from commercial excellence and favorable product mix due to strong sales of our proprietary product offerings.
Operating income
(in millions)
| 2021 | Three months ended June 30, 2020 | 2021 | Change 2020 | Six months ended June 30, | Change | |
|---|---|---|---|---|---|---|
| Gross profit | $626.5 | $490.6 | $135.9 | $1,239.3 | $992.5 | $246.8 |
| Operating expenses | 371.8 | 324.0 | 47.8 | 718.3 | 667.5 | 50.8 |
| Operating income | $254.7 | $166.6 | $88.1 | $521.0 | $325.0 | $196.0 |
Three and six months ended
Gross profit for the three and six months ended June 30, 2021 increased $135.9 million and $246.8 million, respectively, due to the reasons described above. The increase in operating expenses primarily relates to acquisition-related expenses and increased incentive compensation expense due to our strong performance in the first half of 2021.
Net income or loss
(in millions)
| 2021 | Three months ended June 30, 2020 | 2021 | Change 2020 | Six months ended June 30, | Change | |
|---|---|---|---|---|---|---|
| Operating income | $254.7 | $166.6 | $88.1 | $521.0 | $325.0 | $196.0 |
| Interest expense | (51.0) | (92.1) | 41.1 | (102.5) | (186.6) | 84.1 |
| Loss on extinguishment of debt | (3.2) | — | (3.2) | (8.4) | — | (8.4) |
| Other income, net | 14.6 | 4.2 | 10.4 | 16.4 | 5.0 | 11.4 |
| Income tax expense | (57.3) | (18.5) | (38.8) | (104.7) | (36.2) | (68.5) |
| Net income | $157.8 | $60.2 | $97.6 | $321.8 | $107.2 | $214.6 |
Three and six months ended
Net income for the three and six months ended June 30, 2021 increased by $97.6 million and $214.6 million, respectively, primarily driven by the operating income growth detailed above and lower interest expense from the repricings and refinancings of our debt for more favorable interest rates in the second half of 2020 and lower debt. This was partially offset by higher income tax expense as a result of our higher pretax income and a loss on extinguishment of debt related to optional prepayments.
Adjusted EBITDA and Adjusted EBITDA margin
For a reconciliation of Adjusted EBITDA to Net income or loss, the most directly comparable measure under GAAP, see “Reconciliations of non-GAAP financial measures.”
(in millions)
| 2021 Adjusted EBITDA: | Three months ended June 30, 2020 | 2021 | Change 2020 | Six months ended June 30, | Change | |
|---|---|---|---|---|---|---|
| Americas | $251.7 | $197.4 | $54.3 | $503.7 | $387.4 | $116.3 |
| Europe | 123.8 | 88.3 | 35.5 | 254.9 | 180.0 | 74.9 |
| AMEA | 28.5 | 22.5 | 6.0 | 51.1 | 35.9 | 15.2 |
| Corporate | (37.4) | (34.9) | (2.5) | (80.0) | (67.2) | (12.8) |
| Total | $366.6 | $273.3 | $93.3 | $729.7 | $536.1 | $193.6 |
| Adjusted EBITDA margin | 19.7% | 18.5% | 1.2% | 20.0% | 17.9% | 2.1% |
Three months ended
Adjusted EBITDA increased $93.3 million or 34.2%, which included a favorable foreign currency translation impact of $13.5 million or 5.0%. The reasons for the remaining growth of $79.8 million or 29.2%, are discussed below:
In the Americas, Adjusted EBITDA grew $54.3 million or 27.5%, or 26.5% when adjusted for favorable foreign currency translation impact. Gross margin expansion from favorable volume, commercial excellence and product mix was partially offset by increased incentive compensation expense and higher SG&A expenses when compared to reductions in the prior year related to COVID-19 lockdowns.
In Europe, Adjusted EBITDA grew $35.5 million or 40.3%, or 28.8% when adjusted for favorable foreign currency translation impact, due to gross margin expansion from favorable volume and commercial excellence, partially offset by increased incentive compensation expense and higher SG&A expenses when compared to reductions in the prior year related to COVID-19 lockdowns.
In AMEA, Adjusted EBITDA grew $6.0 million or 26.2%, or 19.9% when adjusted for favorable foreign currency translation. In addition to the favorable sales volume, lower bad debt expense contributed to Adjusted EBITDA growth. This was partially offset by increased incentive compensation expense and higher SG&A expenses when compared to reductions in the prior year related to COVID-19 lockdowns.
In Corporate, Adjusted EBITDA declined $2.5 million or 7.0% reflecting higher incentive compensation expense and increased stock-based compensation expense.
Six months ended
Adjusted EBITDA increased $193.6 million or 36.1%, which included a favorable foreign currency translation impact of $24.5 million or 4.5%. The reasons for the remaining growth of $169.1 million or 31.6%, are discussed below:
In the Americas, Adjusted EBITDA grew $116.3 million or 30.0%, or 29.2% when adjusted for favorable foreign currency translation impact for reasons similar to the three month period.
In Europe, Adjusted EBITDA grew $74.9 million or 41.6%, or 31.0% when adjusted for favorable foreign currency translation impact for reasons similar to the three month period.
In AMEA, Adjusted EBITDA grew $15.2 million or 42.2%, or 35.3% when adjusted for favorable foreign currency translation for reasons similar to the three month period.
In Corporate, Adjusted EBITDA declined $12.8 million or 18.9% for reasons similar to the three month period.
Reconciliations of non-GAAP financial measures
The following table presents the reconciliation of net income or loss to Adjusted EBITDA:
(in millions)
| 2021 | Three months ended June 30, 2020 | 2021 | Six months ended June 30, 2020 | |
|---|---|---|---|---|
| Net income | $157.8 | $60.2 | $321.8 | $107.2 |
| Interest expense | 51.0 | 92.1 | 102.5 | 186.6 |
| Income tax expense | 57.3 | 18.5 | 104.7 | 36.2 |
| Depreciation and amortization | 86.1 | 97.8 | 175.1 | 194.3 |
| Loss on extinguishment of debt | 3.2 | — | 8.4 | — |
| Net foreign currency loss (gain) from financing activities | 1.2 | (1.8) | 2.0 | (0.2) |
| Other stock-based compensation expense | 0.7 | 1.1 | 1.3 | — |
| Acquisition-related expenses1 | 21.6 | — | 24.6 | — |
| Integration-related expenses2 | 0.5 | 2.2 | 0.5 | 7.6 |
| Restructuring and severance charges3 | 0.2 | 3.2 | 1.8 | 4.4 |
| Receipt of disgorgement penalty4 | (13.0) | — | (13.0) | — |
| Adjusted EBITDA | $366.6 | $273.3 | $729.7 | $536.1 |
1. Represents legal, accounting, investment banking and consulting fees incurred related to the acquisition of acquired companies.
2. Represents non-recurring direct costs incurred to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
3. Reflects the incremental expenses incurred in the period related to initiatives to increase profitability and productivity. Typical costs included in this caption are employee severance, site-related exit costs, and contract termination costs.
4. As described in note 13 to our unaudited interim financial statements.
Liquidity and capital resources
We fund short-term cash requirements primarily from operating cash flows. Most of our long-term financing is from indebtedness. For the three and six month periods ended June 30, 2021, we generated $263.8 million and $390.7 million of cash from operating activities, respectively, ended the quarter with
$223.0 million of cash and cash equivalents and our availability under credit facilities was $804.6 million. Required debt repayments due in the next twelve months other than required term loan payments are $33.6 million.
Liquidity
The following table presents our primary sources of liquidity:
(in millions)
| June 30, 2021 Receivables facility Revolving credit facility Total Unused availability under credit facilities: | |
|---|---|
| Capacity $300.0 $515.0 | $815.0 |
| Undrawn letters of credit outstanding (8.8) (1.6) | (10.4) |
| Outstanding borrowings — — | — |
| Unused availability $291.2 $513.4 | $804.6 |
| Cash and cash equivalents | 223.0 |
| Total liquidity | $1,027.6 |
We fund short-term cash requirements primarily from operating cash flows. Some of our credit line availability depends upon maintaining a sufficient borrowing base of eligible accounts receivable. We believe that we have sufficient capital resources to meet our liquidity needs.
Our debt agreements include representations and covenants that we consider usual and customary, and our receivables facility and senior secured credit facilities include a financial covenant that becomes applicable for periods in which we have drawn more than 35% of our revolving credit facility under the senior secured credit facilities. In this circumstance, we are not permitted to have combined borrowings on our senior secured credit facilities and secured notes in excess of a pro forma net leverage ratio, as defined. As we had not drawn more than 35% of our revolving credit facility in this period, this covenant was not applicable at June 30, 2021.
At June 30, 2021, $194.1 million or 87.0% of our $223.0 million in cash and cash equivalents was held by our non-U.S. subsidiaries and may be subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply.
Historical cash flows
The following table presents a summary of cash provided by (used in) various activities:
(in millions)
| 2021 Operating activities: | Six months ended June 30, 2020 | Change | |
|---|---|---|---|
| Net income | $321.8 | $107.2 | 214.6 |
| Non-cash items | 236.3 | 241.9 | (5.6) |
| Working capital changes1,2 | (158.7) | (35.2) | (123.5) |
| All other | (8.7) | 28.4 | (37.1) |
| Total | $390.7 | $342.3 | $48.4 |
| Investing activities | $(1,203.9) | $(24.4) | $(1,179.5) |
| Cash paid for acquisitions, net of cash acquired | (1,166.7) | — | (1,166.7) |
| Capital expenditures | (38.5) | (26.1) | (12.4) |
| Financing activities | 777.8 | (86.4) | 864.2 |
1. The amount previously reported as working capital changes for six months ended June 30, 2020 has been revised in the above table to give effect to the correction of an immaterial classification error disclosed in note 1 to our unaudited interim financial statements.
2. Includes changes to our accounts receivable, inventory, contract assets and accounts payable.
Cash flows from operating activities provided $48.4 million more cash in 2021 primarily due to significantly higher net income offset by increased working capital requirements and larger payouts under our incentive compensation plan due to the strong performance of our business.
Investing activities used $1,179.5 million more cash in 2021, reflecting cash paid to acquire Ritter GmbH and RIM Bio, as well as increased capital spending.
Financing activities provided $864.2 million more cash in 2021 primarily due to the issuance of new tranches of Euro term loans to finance the acquisition of Ritter GmbH, offset by optional prepayments on our existing term loans under our senior secured credit facilities.
Free cash flow
(in millions)
| 2021 | Six months ended June 30, 2020 | Change | |
|---|---|---|---|
| Net cash provided by operating activities | $390.7 | $342.3 | $48.4 |
| Acquisition-related expenses paid | 24.6 | — | 24.6 |
| Capital expenditures | (38.5) | (26.1) | (12.4) |
| Free cash flow | $376.8 | $316.2 | $60.6 |
Free cash flow was $60.6 million higher in 2021 due to the changes in cash flows from operating activities noted above, which included $24.6 million of non-recurring costs related to the acquisitions of
Ritter and RIM Bio, offset by an increase in capital spending. Refer to “Reconciliations of non-GAAP financial measures” for disclosure regarding acquisition-related expenses.
Indebtedness
For information about our indebtedness, refer to the section entitled “Liquidity” and note 10 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements.”
New accounting standards
For information about new accounting standards, see note 2 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements.”
Controls and procedures
As filed, 1,004 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management’s evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2021, the design and operation of our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.
Changes in internal control over financial reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the fiscal quarter ended June 30, 2021 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
Risk factors
As filed, 316 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report. There have been no material changes to the risk factors disclosed in Part I—Item 1A of the Annual Report.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $1.86bn | us-gaap:Revenues |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $3.64bn | us-gaap:Revenues |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $1.23bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $2.40bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-04-01 to 2021-06-30 | $626.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2021-01-01 to 2021-06-30 | $1.24bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2021-04-01 to 2021-06-30 | $371.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2021-01-01 to 2021-06-30 | $718.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | $254.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | $521.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-04-01 to 2021-06-30 | $51.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-06-30 | $102.5m | us-gaap:InterestExpense |
| Income tax | 3 months2021-04-01 to 2021-06-30 | $57.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-06-30 | $104.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | $157.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | $321.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | $0.24 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | $0.49 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | $0.24 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | $0.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-01 to 2021-06-30 | 591,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-06-30 | 590,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | $390.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $38.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $223.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $2.42bn | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $11.25bn | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $1.38bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $8.26bn | us-gaap:Liabilities |
| Long-term debt | At period end2021-06-30 | $5.61bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-06-30 | $39.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2021-06-30 | $2.99bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001722482-21-000212. Last ingested by Listed: Nov 13, 2026, 16:45 ET. Listed shows no prices and gives no investment advice.